Method for treating type 1 diabetes using .alpha.-interferon and/or .beta.-i

• US 5,780,021 A
• Filed: 03/05/1993
• Issued: 07/14/1998
• Est. Priority Date: 03/05/1993
• Status: Expired due to Fees

• Current Assignee: Georgetown University
• Original Assignee: Georgetown University
• Inventors: Sobel, Douglas O.
• Primary Examiner(s): Teng, Sally P.
• Application Number:
  US08/026,758
• Time in Patent Office: 1,957 Days
• Field of Search: 514/2, 530/351, 424/85.6, 424/85.4, 424/85.7, 435/69.1, 435/69.51
• US Class Current: 424/85.4
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/212 IFN-alpha
• CPC Class Codes: A61K 38/215 IFN-beta
• CPC Class Codes: C07K 14/56 IFN-alpha
• CPC Class Codes: C07K 14/565 IFN-beta

Abstract

A method is provided for preventing or treating an autoimmune disorder and/or recurrent autoimmune disorder in a transplant tissue in a mammal, which entails administering an effective amount of a single subtype of α- and/or β-interferon or a hybrid or analog of either or mixture thereof to the mammal.

Claims

1. A method of treating Type 1 diabetes in a mammal, which method comprises administering to a mammal having Type 1 diabetes mellitus an effective amount of at least one naturally-occurring Type 1 interferon, a synthetic Type 1 interferon analog or a hybrid Type 1 interferon, wherein said Type 1 interferon analog or hybrid binds to the same receptor as a naturally occurring Type 1 interferon.

2. The method of claim 1, wherein said mammal is a human.

3. The method of claim 1, wherein an α

- or β

-interferon or a synthetic analog thereof is administered.

4. The method of claim 1, wherein said effective amount ranges from about 1×

10⁵ units to about 10×

10⁷ units for administration.

5. The method of claim 4, wherein the effective amount ranges from about 1×

10⁶ to about 75×

10⁶ units for administration.

6. The method of claim 1, wherein a naturally-occurring α

-interferon or β

-interferon, synthetic analog thereof, or hybrid α

- or β

-interferon is administered.

7. The method of claim 6, wherein a naturally-occurring α

-interferon or β

-interferon is administered.

8. The method of claim 1, wherein said hybrid Type I interferon is rHuIFNα

-A/D Bgl II.

9. A method of treating an asymptomatic preclinical state of Type 1 diabetes mellitus in a mammal at risk of developing Type 1 diabetes mellitus, which comprises administering to said mammal an effective amount of at least one naturally occurring Type 1 interferon, a synthetic Type 1 interferon analog, or a hybrid Type 1 interferon wherein said Type 1 interferon analog or hybrid binds the same receptor as a naturally occurring Type 1 interferon.

10. The method of claim 9, wherein said mammal is a human.

11. A method of treating recurrent Type 1 diabetes mellitus in a mammal having recurrent Type 1 diabetes mellitus, comprising administering an effective amount of at least one naturally occurring Type 1 interferon, a synthetic Type 1 interferon analog, or a hybrid Type 1 interferon wherein said Type 1 interferon analog or hybrid binds the same receptor as a naturally occurring Type 1 interferon.

12. The method of claim 11, wherein said mammal is a human.

13. The method of claim 11, wherein the mammal which is treated comprises transplanted pancreatic or islet tissue.

14. The method of claim 13, wherein a naturally-occurring α

- or β

-interferon or a synthetic analog thereof is administered.

15. The method of claim 11, wherein said effective amount ranges from about 1×

10⁵ units to about 10×

10⁷ units per administration.

16. The method of claim 15, wherein said effective amount ranges from about 1×

10⁶ to about 75×

10⁶ units per administration.

17. The method of claim 11, wherein a naturally-occurring α

-interferon or β

-interferon or a synthetic, analog, or hybrid thereof is administered.

18. The method of claim 17, wherein a naturally-occurring α

-interferon or β

-interferon is administered.

19. The method of claim 11, wherein a naturally-occurring α

-interferon or β

-interferon, or a hybrid or synthetic analog thereof is administered.

20. A method of treating Type 1 diabetes in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of α

-interferon.

21. A method of preventing Type 1 diabetes in a mammal comprising administering to a mammal at risk of developing Type 1 diabetes mellitus an effective amount of at least one naturally-occurring Type 1 interferon, a synthetic Type 1 interferon analog or a hybrid Type 1 interferon, wherein said Type 1 interferon analog or hybrid binds to the same receptor as a naturally occurring Type 1 interferon.

22. The method of claim 21, wherein a naturally-occurring α

-interferon or β

-interferon, or a hybrid or synthetic analog thereof is administered.

23. A method of preventing recurrent Type 1 diabetes mellitus in a mammal at risk of developing recurrent Type 1 diabetes mellitus comprising administering an effective amount of at least one naturally occurring Type 1 interferon, a synthetic Type interferon analog, or a hybrid Type 1 interferon, wherein said Type 1 interferon analog or hybrid binds the same receptor as a naturally occurring Type 1 interferon.

24. The method of claim 23, wherein a naturally-occurring α

-interferon or β

-interferon, or an analog thereof is administered.